亿帆医药(002019.SZ)：注射用硫酸艾沙康唑获得药品注册证书

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for injectable isavuconazole from the National Medical Products Administration on September 15, 2025. This drug is an anti-infective medication used for treating adult patients with invasive aspergillosis and invasive mucormycosis [1]. Company Summary - Yifan Pharmaceutical's subsidiary, Hefei Yifan Biopharmaceutical, has been granted approval for injectable isavuconazole, indicating a significant milestone in expanding its product portfolio in the anti-infective segment [1]. - The approval of injectable isavuconazole positions the company to address critical medical needs in treating serious fungal infections, potentially enhancing its market presence and revenue streams [1]. Industry Summary - The approval of injectable isavuconazole reflects ongoing advancements in the pharmaceutical industry, particularly in the development of treatments for invasive fungal infections, which are increasingly recognized as significant health threats [1]. - The introduction of new anti-infective drugs like isavuconazole is crucial for improving patient outcomes and addressing the growing concerns over fungal infections in immunocompromised populations [1].